Platelet Activation Signatures for Mechanical Shear Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring platelet activation in patients with mechanical circulatory support devices are inadequate, failing to detect early alterations in platelet function due to mechanical activation and distinguishing them from biochemical activation, leading to thrombotic complications.
Innovation Solution
The use of biochemical markers such as phosphatidylserine, thrombin, integrin GPIIb/IIIa, glycoprotein GP Ib, P-selectin, platelet size, microparticle generation, and lipidomic profile to create composite molecular signatures that can accurately monitor mechanically activated platelets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard platelet activation markers are monitored, then platelet function alterations can be evaluated, but mechanically activated platelets cannot be distinguished from biochemically activated platelets
Solution Approach 1:
The patent segments the platelet activation detection into two distinct components: (1) standard activation markers monitored by conventional methods, and (2) mechanical activation-specific markers monitored by flow cytometry. This segmentation allows simultaneous evaluation of general platelet activation status while specifically identifying mechanically activated platelets through unique markers such as phosphatidylserine externalization and specific integrin conformations.
Solution Approach 2:
The patent introduces flow cytometry as an intermediary measurement technique that bridges the gap between standard platelet activation monitoring and mechanical activation detection. Flow cytometry enables the use of fluorescently labeled antibodies to detect mechanical activation-specific markers on individual platelets, providing a mediator that translates mechanical activation events into quantifiable optical signals distinguishable from biochemical activation.
2Reliability
If aggressive clot prevention therapy is applied, then thrombotic complications may be reduced, but pump thrombosis remains complex to diagnose and carries significant morbidity
Solution Approach 1:
The patent implements preliminary detection of mechanical platelet activation as an early warning system before pump thrombosis develops. By continuously monitoring mechanical activation-specific markers and identifying trends in activation levels, the system enables early intervention with adjusted anticoagulation therapy before full-thickness thrombosis occurs, making diagnosis straightforward through biochemical marker analysis rather than complex imaging or surgical exploration.
Solution Approach 2:
The patent establishes a feedback loop where mechanical platelet activation markers are continuously monitored and used to guide adjustments in anticoagulation therapy. The flow cytometry-based detection provides real-time feedback on platelet activation status, allowing clinicians to titrate clot prevention therapy to maintain activation levels within a safe range, thereby preventing both thrombosis and bleeding complications.
3Measurement precision
If multiple platelet activation markers are monitored, then platelet function alterations can be assessed, but the complexity of the monitoring system increases
Solution Approach 1:
The patent leverages the universality of flow cytometry technology to monitor multiple platelet activation markers simultaneously through a single platform. Flow cytometry can detect various fluorescently labeled antibodies bound to different platelet surface markers in parallel, enabling comprehensive assessment of mechanical activation status without requiring separate testing systems for each marker.
Solution Approach 2:
The patent merges the monitoring of mechanical activation-specific markers with standard platelet activation marker assessment into a unified flow cytometry-based protocol. By combining these monitoring approaches, the system achieves comprehensive platelet function assessment while utilizing a single analytical platform, thereby reducing overall system complexity compared to using multiple separate testing systems.
Data Source
AI summary
Biochemical markers that can be measured to determine the level of mechanical activation of a population of platelets are provided, and their use to prepare molecular signatures thereof are provided. The markers include phosphatidylserine, thrombin, integrin GPIIb/IIIa activation, glycoprotein GP Ib, P-selectin; platelet size; microparticle generation, or lipidomic profile of the membrane. The disclosed markers, measurement thereof, and signatures composed therefrom can be used in a variety of methods of patient selection, treatment monitoring, treatment selection, including both devices and active agents, and methods of treating subjects in need thereof, particularly humans. Examples of such methods include, but are not limited to, reducing shear-activated platelets; selecting a blood-contacting medical device; selecting between two or more medical devices; identifying a subject at a risk of developing a thrombogenic event; monitoring the prophylactic treatment of a subject; selecting a mechanoceutical agent; and delivering an agent to a subject.